Precision medicine, Niraparib (PARP inhibitor, PARPi) and radiation have been shown to synergize to inhibit tumors both in vitro and in vivo in EGFR-mutated non-small cell lung cancer [85]. Here, PARP1 is linked to non-small cell lung carcinoma.